Optimizing the dose of hydroxyurea therapy for patients with β-thalassemia intermedia (Hb E-β-thalassemia): a single center study from eastern India. (avaa uuden ikkunan)

Bohara VV, Ray S, Chakrabarti P, Ray SS, Nath UK, Chaudhuri U.

Lähde‎: Hemoglobin 2014;38(1):44-8.

Arkistoitu‎: PubMed 24144212

DOI‎: 10.3109/03630269.2013.845844

https://www.ncbi.nlm.nih.gov/pubmed/24144212 (avaa uuden ikkunan)

Hydroxyurea in thalassemia intermedia--a promising therapy. (avaa uuden ikkunan)

Dixit A, Chatterjee TC, Mishra P, Choudhry DR, Mahapatra M, Tyagi S, Kabra M, Saxena R, Choudhry VP.

Lähde‎: Ann Hematol 2005;84(7):441-6.

Arkistoitu‎: PubMed 15838670

DOI‎: 10.1007/s00277-005-1026-4

https://www.ncbi.nlm.nih.gov/pubmed/15838670 (avaa uuden ikkunan)

Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassaemia: a genotypic and phenotypic study. (avaa uuden ikkunan)

Italia KY, Jijina FF, Merchant R, Panjwani S, Nadkarni AH, Sawant PM, Nair SB, Ghosh K, Colah RB.

Lähde‎: J Clin Pathol 2010;63(2):147-50.

Arkistoitu‎: PubMed 20154037

DOI‎: 10.1136/jcp.2009.070391

https://www.ncbi.nlm.nih.gov/pubmed/20154037 (avaa uuden ikkunan)

Echocardiographic finding in beta-thalassemia intermedia and major: absence of pulmonary hypertension following hydroxyurea treatment in beta-thalassemia intermedia. (avaa uuden ikkunan)

Karimi M, Borzouee M, Mehrabani A, Cohan N.

Lähde‎: Eur J Haematol 2009;82(3):213-8.

Arkistoitu‎: PubMed 19077048

DOI‎: 10.1111/j.1600-0609.2008.01192.x

https://www.ncbi.nlm.nih.gov/pubmed/19077048 (avaa uuden ikkunan)

Effect of combination therapy of hydroxyurea with l-carnitine and magnesium chloride on hematologic parameters and cardiac function of patients with beta-thalassemia intermedia. (avaa uuden ikkunan)

Karimi M, Mohammadi F, Behmanesh F, Samani SM, Borzouee M, Amoozgar H, Haghpanah S.

Lähde‎: Eur J Haematol 2010;84(1):52-8.

Arkistoitu‎: PubMed 19799627

DOI‎: 10.1111/j.1600-0609.2009.01356.x

https://www.ncbi.nlm.nih.gov/pubmed/19799627 (avaa uuden ikkunan)

Reduction of the clinical severity of sickle cell/beta-thalassemia with hydroxyurea: the experience of a single center in Greece. (avaa uuden ikkunan)

Loukopoulos D, Voskaridou E, Kalotychou V, Schina M, Loutradi A, Theodoropoulos I.

Lähde‎: Blood Cells Mol Dis 2000;26(5):453-66.

Arkistoitu‎: PubMed 11112383

DOI‎: 10.1006/bcmd.2000.0328

https://www.ncbi.nlm.nih.gov/pubmed/11112383 (avaa uuden ikkunan)

Fetal globin stimulant therapies in the beta-hemoglobinopathies: principles and current potential. (avaa uuden ikkunan)

Perrine SP.

Lähde‎: Pediatr Ann 2008;37(5):339-46.

Arkistoitu‎: PubMed 18543545

https://www.ncbi.nlm.nih.gov/pubmed/18543545 (avaa uuden ikkunan)

Single and combination drug therapy for fetal hemoglobin augmentation in hemoglobin E-beta 0-thalassemia: Considerations for treatment. (avaa uuden ikkunan)

Singer ST, Kuypers FA, Olivieri NF, Weatherall DJ, Mignacca R, Coates TD, Davies S, Sweeters N, Vichinsky EP.

Lähde‎: Ann N Y Acad Sci 2005;1054:250-6.

Arkistoitu‎: PubMed 16339672

DOI‎: 10.1196/annals.1345.031

https://www.ncbi.nlm.nih.gov/pubmed/16339672 (avaa uuden ikkunan)

Treatment of beta-thalassemia patients with recombinant human erythropoietin: effect on transfusion requirements and soluble adhesion molecules. (avaa uuden ikkunan)

Chaidos A, Makis A, Hatzimichael E, Tsiara S, Gouva M, Tzouvara E, Bourantas KL.

Lähde‎: Acta Haematol 2004;111(4):189-95.

Arkistoitu‎: PubMed 15153710

DOI‎: 10.1159/000077551

https://www.ncbi.nlm.nih.gov/pubmed/15153710 (avaa uuden ikkunan)

Efficacy of erythropoietin on dialysis in patients with beta thalassemia minor. (avaa uuden ikkunan)

Di Iorio B, De Nicola L, Bellizzi V, Minutolo R, Zamboli P, Rubino R, Fuiano G, Conte G.

Lähde‎: Blood Purif 2004;22(5):453-60.

Arkistoitu‎: PubMed 15359104

DOI‎: 10.1159/000080729

https://www.ncbi.nlm.nih.gov/pubmed/15359104 (avaa uuden ikkunan)

The role of recombinant human erythropoietin in the treatment of thalassemia. (avaa uuden ikkunan)

Rachmilewitz EA, Aker M.

Lähde‎: Ann N Y Acad Sci 1998;850:129-38.

Arkistoitu‎: PubMed 9668535

https://www.ncbi.nlm.nih.gov/pubmed/9668535 (avaa uuden ikkunan)

Darbepoetin alfa for the treatment of anaemia in alpha- or beta- thalassaemia intermedia syndromes. (avaa uuden ikkunan)

Singer ST, Vichinsky EP, Sweeters N, Rachmilewitz E.

Lähde‎: Br J Haematol 2011;154(2):281-4.

Arkistoitu‎: PubMed 21496003

DOI‎: 10.1111/j.1365-2141.2011.08617.x

https://www.ncbi.nlm.nih.gov/pubmed/21496003 (avaa uuden ikkunan)

The emerging role of fetal hemoglobin induction in non-transfusion-dependent thalassemia. (avaa uuden ikkunan)

Thein SL.

Lähde‎: Blood Rev 2012;26 Suppl 1:S35-9.

Arkistoitu‎: PubMed 22631042

DOI‎: 10.1016/S0268-960X(12)70011-5

https://www.ncbi.nlm.nih.gov/pubmed/22631042 (avaa uuden ikkunan)